MURRYSVILLE, Pa., Jan. 13 /PRNewswire-FirstCall/ -- Respironics, Inc. , a recognized resource in the medical device market, announced today that it intends to release its fiscal year 2006, second quarter results for the period ending December 31, 2005, on Thursday, January 26, 2006. In conjunction with this release and to review the Company’s results and business outlook, Respironics will host a conference call that will be broadcast simultaneously live over the Internet.
Individuals wishing to participate on the Webcast, to be held at 8:30 a.m. EST on Thursday, January 26, 2006, can access the event at the Company’s web site at http://www.respironics.com.
Please allow extra time prior to the call to visit the site and download the streaming media software required to listen to the Internet broadcast. The online archive of the broadcast will be available within 2 hours of the live call and will be available for 30 days.
Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and health care providers. Respironics markets its products in over 125 countries and employs over 4,000 associates worldwide. Further information can be found on the Company’s Web site: http://www.respironics.com.
This document contains forward-looking statements, including statements relating to, among other things, developments in the health care industry, third-party reimbursement policies and practices, effectiveness of programs, future sales and acceptance of the company’s products and Power Programs., new product development, anticipated cost savings and regulatory requirements, regulatory enforcement actions, anticipated results from acquisitions, foreign operations, growth rates of foreign markets, and anticipated levels of earnings and revenues, all of which are subject to change. Actual results may differ materially from those described in any forward-looking statements. Additional information on potential factors that could affect the company’s financial results are included in the reports filed with the SEC, including the reports on Form 10- K, 10-Q and 8-K.
Respironics, Inc.
CONTACT: Dan Bevevino, Vice President & CFO of Respironics, Inc.,+1-724-387-5235; or Joe Calabrese, General Contact, +1-212-827-3772, orJulie Tu, Analyst Information, +1-212-827-3776, both of Financial RelationsBoard, for Respironics, Inc.
Web site: http://www.respironics.com/
